Targeted drug delivery into the colon is highly desirable for local treatment of a variety of bowel diseases such as ulcerative colitis, Crohn’s disease, amoebiasis, colonic cancer, local treatment of colonic pathologies, and systemic delivery of protein and peptide drugs, NSAIDs, steroids.
The colon is believed to be a suitable absorption site for peptides and protein drugs for the following reasons; (i) less diversity, and intensity of digestive enzymes, (ii) less proteolytic activity of colon mucosa than that of small intestine.
CRITERIA: Drugs used for local effects in colon against GIT diseases.
Drugs poorly absorbed from upper GIT.
Drugs for colon cancer.
Drugs that degrade in stomach and small intestine.
Drugs that undergo extensive first pass metabolism.
Drugs for targeting.
Colon targeted drug delivery aims to treat diseases of the colon like ulcerative colitis and intestinal cancer. It delivers drugs that would otherwise be degraded in the stomach directly to the colon, minimizing side effects. Various approaches are used, including coating drugs with polymers that dissolve at the pH of the colon, or conjugating drugs to carriers that are cleaved by colonic enzymes. This allows targeted treatment of colon diseases while reducing dosing and systemic side effects compared to traditional oral drug delivery.
The document discusses colon targeted drug delivery. It begins with an introduction describing the desirability of targeted colon delivery. It then discusses the anatomy of the colon, criteria for drug selection, and various approaches for colon targeting including pH sensitive polymers, delayed release systems, microbially triggered delivery, and innovative devices. It also covers evaluation methods and concludes that developing an effective oral colon delivery system remains a challenge that requires consideration of the entire gastrointestinal tract environment.
The document discusses various approaches for targeting drug delivery to the colon, including conventional and new approaches. Conventional approaches include pH sensitive polymer coatings, delayed release systems, and use of prodrugs. Newer approaches discussed are osmotic controlled delivery systems, intestinal pressure controlled colon delivery capsules, nanoparticle systems, pulsincap systems, and azo hydrogels. The colon's anatomy, physiology, and factors affecting drug absorption are also summarized.
This document discusses colon targeted drug delivery systems. It begins by stating that colon targeted delivery is used to deliver substances that are degraded in the stomach, such as proteins and peptides. It then discusses various approaches to colon targeted delivery including pH sensitive polymers, delayed release systems, and microbial triggered delivery. The document covers the advantages of colon targeted systems, limitations, factors affecting delivery like gastric emptying and colonic pH, and provides examples of technologies like pulsincap and osmotic systems. It concludes with a discussion of evaluation methods and references.
The document discusses colon drug delivery systems. It describes the colon as a site for local and systemic drug delivery to treat diseases like Crohn's disease and ulcerative colitis. Various methods are described for targeting drug delivery to the colon, including the use of prodrugs, pH-sensitive polymers, biodegradable polymers, and timed release systems. Advantages of colon targeting include treatment of local colon diseases, bypassing first-pass metabolism, and reduced side effects. Limitations include multiple manufacturing steps and potential drug binding in the colon. The document then discusses various approaches for colon drug delivery, including the use of pH-sensitive polymers, time-dependent systems, microbially-triggered delivery, bioadhesive systems,
Colon Specific Drug Delivery System: Basics and ApproachesNone
Colon drug delivery and approaches can target drugs specifically to the colon through various pH sensitive, time controlled, or microbially triggered mechanisms. Drugs suitable for colon targeting include those for inflammatory bowel disease, colon cancer, protein/peptide delivery, and infectious diseases. Approaches include pH sensitive polymer coatings, time controlled systems, microbially triggered delivery using enzymes, and novel approaches like pressure controlled, osmotic controlled, pulsincap, and port systems. Evaluation involves in vitro dissolution and degradation testing as well as in vivo parameters like drug delivery index and animal studies.
This document provides information on a presentation about pharmaceutical approaches to colon targeted drug delivery systems for treating diseases like Crohn's disease. It discusses the anatomy and physiology of the colon, diseases associated with the colon, drug absorption in the colon, and various approaches for colon targeted drug delivery including pH sensitive polymers, time controlled release systems, microbiologically triggered systems, and new approaches like pressure controlled, pulsatile, and multi particulate systems. The presentation aims to highlight the advantages and limitations of different colon targeted drug delivery approaches.
Colon targeted drug delivery aims to treat diseases of the colon like ulcerative colitis and intestinal cancer. It delivers drugs that would otherwise be degraded in the stomach directly to the colon, minimizing side effects. Various approaches are used, including coating drugs with polymers that dissolve at the pH of the colon, or conjugating drugs to carriers that are cleaved by colonic enzymes. This allows targeted treatment of colon diseases while reducing dosing and systemic side effects compared to traditional oral drug delivery.
The document discusses colon targeted drug delivery. It begins with an introduction describing the desirability of targeted colon delivery. It then discusses the anatomy of the colon, criteria for drug selection, and various approaches for colon targeting including pH sensitive polymers, delayed release systems, microbially triggered delivery, and innovative devices. It also covers evaluation methods and concludes that developing an effective oral colon delivery system remains a challenge that requires consideration of the entire gastrointestinal tract environment.
The document discusses various approaches for targeting drug delivery to the colon, including conventional and new approaches. Conventional approaches include pH sensitive polymer coatings, delayed release systems, and use of prodrugs. Newer approaches discussed are osmotic controlled delivery systems, intestinal pressure controlled colon delivery capsules, nanoparticle systems, pulsincap systems, and azo hydrogels. The colon's anatomy, physiology, and factors affecting drug absorption are also summarized.
This document discusses colon targeted drug delivery systems. It begins by stating that colon targeted delivery is used to deliver substances that are degraded in the stomach, such as proteins and peptides. It then discusses various approaches to colon targeted delivery including pH sensitive polymers, delayed release systems, and microbial triggered delivery. The document covers the advantages of colon targeted systems, limitations, factors affecting delivery like gastric emptying and colonic pH, and provides examples of technologies like pulsincap and osmotic systems. It concludes with a discussion of evaluation methods and references.
The document discusses colon drug delivery systems. It describes the colon as a site for local and systemic drug delivery to treat diseases like Crohn's disease and ulcerative colitis. Various methods are described for targeting drug delivery to the colon, including the use of prodrugs, pH-sensitive polymers, biodegradable polymers, and timed release systems. Advantages of colon targeting include treatment of local colon diseases, bypassing first-pass metabolism, and reduced side effects. Limitations include multiple manufacturing steps and potential drug binding in the colon. The document then discusses various approaches for colon drug delivery, including the use of pH-sensitive polymers, time-dependent systems, microbially-triggered delivery, bioadhesive systems,
Colon Specific Drug Delivery System: Basics and ApproachesNone
Colon drug delivery and approaches can target drugs specifically to the colon through various pH sensitive, time controlled, or microbially triggered mechanisms. Drugs suitable for colon targeting include those for inflammatory bowel disease, colon cancer, protein/peptide delivery, and infectious diseases. Approaches include pH sensitive polymer coatings, time controlled systems, microbially triggered delivery using enzymes, and novel approaches like pressure controlled, osmotic controlled, pulsincap, and port systems. Evaluation involves in vitro dissolution and degradation testing as well as in vivo parameters like drug delivery index and animal studies.
This document provides information on a presentation about pharmaceutical approaches to colon targeted drug delivery systems for treating diseases like Crohn's disease. It discusses the anatomy and physiology of the colon, diseases associated with the colon, drug absorption in the colon, and various approaches for colon targeted drug delivery including pH sensitive polymers, time controlled release systems, microbiologically triggered systems, and new approaches like pressure controlled, pulsatile, and multi particulate systems. The presentation aims to highlight the advantages and limitations of different colon targeted drug delivery approaches.
Colon-specific drug delivery systems (CDDS) aim to release drugs in the colon to treat diseases localized in the region. The colon offers advantages for drug absorption and many approaches have been developed. CDDS rely on the colon's distinct pH, transit time, microflora and enzymes to trigger drug release. They include pH-sensitive coatings, prodrugs, polysaccharide matrices and time-delayed systems. In vitro and in vivo tests evaluate release profiles under gastrointestinal conditions while imaging techniques track systems in the colon. CDDS provide localized treatment with fewer side effects compared to traditional therapies.
This document discusses pharmaceutical approaches to colon targeted drug delivery systems. It begins with an introduction to colon targeted drug delivery and the advantages of this approach. It then describes the anatomy and physiology of the colon, factors governing colonic drug delivery, and various strategies that can be used for targeting drugs to the colon. These strategies include pH dependent delivery, time dependent delivery, pressure dependent delivery, and bacteria dependent delivery. The document also discusses different approaches for colon targeting, including coating with pH sensitive polymers and formulation of timed release systems. It reviews evaluation methods and some marketed products for colon targeted delivery systems, and concludes with discussing future prospects for this drug delivery approach.
RECENT ADVANCES IN COLON TARGETED DRUG DELIVERYVarun Girme
This document summarizes recent advances in colon targeted drug delivery. It discusses the anatomy and physiology of the colon, pharmaceutical approaches for targeting drugs to the colon like prodrug conjugates and coating technologies, evaluation methods for colon delivery systems including in vitro dissolution tests and gamma scintigraphy imaging. It also presents a case study on the formulation of 5-fluorouracil loaded chitosan nanoparticles with Eudragit S100 coating for colon cancer treatment, showing enhanced localized drug release at colonic pH.
FORMULATION AND INVITRO EVALUATION OF COLON SPECIFIC DRUG DELIVERY SYSTEM BY ...alok prakash kar
The document describes the formulation and in vitro evaluation of a colon-specific drug delivery system containing metronidazole. Metronidazole tablets were prepared using different polymers like ethyl cellulose, cellulose acetate butyrate, and Eudragit polymers. The tablets were then coated with various polymer coating suspensions. The coated tablets were evaluated for film thickness, weight gain, hardness, disintegration time, and drug release. The results showed that the coating thickness and weight gain increased with increasing polymer concentration in the coating suspension. The coated tablets had suitable hardness and disintegration times while sustaining drug release in the acidic environment of the stomach.
This presentation related to targeted drug delivery system particularly to colonic region. It includes various approaches for colonic delivery of drug.
Colon specific drug delivery system approaches and applicationTukaram Patil
This document discusses colon specific drug delivery approaches and applications. It begins with an introduction explaining the advantages of targeting drug delivery to the colon and protecting drugs from the upper gastrointestinal tract. It then discusses various factors that affect colonic drug absorption and several primary and new approaches for colon targeted drug delivery systems, including pH sensitive polymers, delayed release systems, and microbial triggered delivery. Examples of different delivery approaches like pulsincap systems, pressure controlled systems, and prodrug approaches are also described. The document concludes that colon targeted delivery offers benefits over traditional systems and novel approaches provide more specific delivery than primary methods.
This document summarizes a seminar presentation on colon-specific drug delivery. It discusses targeting delivery of drugs to the colon to treat diseases like ulcerative colitis and Crohn's disease. Various pharmaceutical approaches for colon-specific delivery are described, including pH sensitive systems, microbial triggered systems, and time release systems. Platform technologies for colon delivery like PULSINCAP and OROS-CT are also outlined. The document concludes that colonic drug delivery presents many challenges but also opportunities to improve therapy for colonic diseases.
This document provides an overview of colon specific drug delivery systems. It discusses the advantages of targeting drug delivery to the colon which includes reduced dosing, lower side effects, and improved patient compliance. It also reviews some limitations such as multiple manufacturing steps and potential for drug degradation by colonic microflora. The document then examines the anatomy and physiology of the colon, factors that influence colonic drug delivery such as pH and transit time, and how drugs are absorbed in the colon. It concludes by outlining several approaches to colon specific drug delivery including pH dependent coatings, time release systems, prodrugs activated by colonic bacteria, and the use of carriers degraded by colonic microflora.
colon drug delivery- advantage and disadvantage of colon delivery, anatomy of colon in healthy and diseased state , different approaches (conventional and new) for colon delivery, in vitro and in vivo evaluation
Colon-specific drug delivery (CDDS) aims to target drug release and absorption in the colon for local treatment of colonic diseases or systemic delivery of proteins and peptides. The document discusses the anatomy and physiology of the colon, factors governing colonic drug delivery, and various pharmaceutical approaches for CDDS including pH-sensitive systems, microbially triggered systems, and timed or controlled release platforms. Evaluation methods for CDDS include in vitro drug release tests under simulated gastric and intestinal conditions and in vitro enzymatic degradation assays.
The document discusses colon targeted drug delivery systems. It begins by defining colon targeted drug delivery as targeting drugs to the lower parts of the GI tract, mainly the large intestine. This is done for various objectives like reducing dosing frequency or delivering drugs that would otherwise be degraded. Approaches to colon targeting include pH sensitive coatings, microbially triggered systems, and timed release. Evaluation methods include in vitro dissolution tests and studies using animal models. Key advantages are site specific delivery and protecting drugs from degradation, while challenges include multiple manufacturing steps and drug binding in the colon.
This document discusses various pharmaceutical approaches for colon specific drug delivery systems. It begins with an introduction to colon specific drug delivery and the physiological considerations. It then describes various approaches in detail, including covalent linkage of drugs to carriers like azo conjugates, cyclodextrin conjugates, and polymeric prodrugs. It also discusses approaches to deliver intact molecules to the colon using coatings with pH sensitive or biodegradable polymers, embedding in matrices, timed release systems, and more. The document provides examples and details for each approach. It concludes with a brief section on evaluating colon specific drug delivery systems.
This document discusses colon targeted drug delivery systems. The major goals of targeted drug delivery are to selectively deliver drugs to the colon at therapeutic concentrations while limiting access to non-target sites. Approaches to colon targeted delivery include pH sensitive polymers, time dependent systems, and formulations triggered by colonic microflora. Several marketed drugs use these approaches including mesalamine, budesonide, and olsalazine. Challenges to colon delivery include biological barriers in the GI tract, variation in gastric emptying and colonic pH, and impact of colonic microflora on drug activity.
The document discusses drug delivery to the colon and various approaches for targeted colon drug delivery systems. It provides information on the anatomy and physiology of the colon, factors influencing drug absorption in the colon, and diseases associated with the colon. Various primary and new approaches for colon targeted drug delivery are described, including pH sensitive polymers, time controlled systems, and microbiologically triggered systems. Evaluation methods for these systems include in vitro and in vivo testing.
This document discusses colon-specific drug delivery systems. It begins with an introduction to colon targeting and why it is important for treating colonic disorders. It then covers factors to consider in design such as colon anatomy, pH, transit time and microflora. Approaches discussed include pH dependent, time dependent and bacteria dependent systems. It evaluates both in vitro and in vivo methods for testing colon delivery systems.
Introduction, Anatomy of colon, Advantage of colon drug delivery system, Disadvantage of colon drug delivery system, Factors influencing CDDS, Approaches of CDDS, Evaluation of CDDS
Pulsatile drug delivery systems presentationchiranjibi68
This seminar discusses pulsatile drug delivery systems, which deliver drugs according to circadian rhythms to time their release when diseases are most active. Such systems provide a lag time followed by a rapid and complete drug release. This allows drugs to be delivered at the right time, amount, and site of action. Pulsatile delivery provides benefits like increased absorption, site targeting of drugs, reduced dosing, and less side effects. Various methods were presented including single and multiple unit systems using coatings that erode, rupture or allow osmotic pumping at the desired time. Marketed technologies like OROS and Pulsincap were highlighted. Pulsatile delivery holds promise for improving treatment of chronic diseases like asthma, arthritis and
DESIGN AND ASSESSMENT OF COLON SPECIFIC DRUG DELIVERY OF CELECOXIB USING PU...Lakshmi
The document summarizes the design and assessment of a colon-specific drug delivery system for celecoxib using pulsincap technique. Celecoxib microcrystals were prepared using a rapid solvent change method and evaluated. The microcrystals were then used to prepare pulsincaps containing hydrogel plugs to provide a lag time before drug release. In vitro drug release studies were conducted on the pulsincaps to assess their ability to deliver celecoxib in a pulsatile manner to the colon. The aim was to improve solubility, target delivery to the colon, and minimize dosing frequency for the treatment of rheumatoid arthritis.
This document presents information on colon targeted drug delivery systems. It discusses the colon as a site for drug absorption and lists some advantages of colon targeted delivery such as reduced dosing frequency and protection of drugs from degradation in the stomach and small intestine. It describes various approaches for colon targeting including prodrug, pH dependent, time dependent, and bacterial activated systems. It provides examples of marketed colon targeted formulations and discusses factors that can influence drug absorption in the colon such as gastrointestinal diseases and transit time.
This document summarizes colon targeted drug delivery systems. It discusses pH dependent systems, time dependent systems, and microbially triggered systems as primary approaches. It also discusses newer approaches like pressure controlled colon delivery capsules and complex delivery systems (CODES). Advantages of colon targeted delivery include protection of drugs from degradation in the stomach and small intestine and targeting delivery to the colon for local treatment of diseases like IBD or systemic delivery of proteins and peptides. Novel drug delivery systems discussed include nano systems for targeted delivery to the colon to treat diseases like IBD and colon cancer.
Colon-specific drug delivery systems (CDDS) aim to release drugs in the colon to treat diseases localized in the region. The colon offers advantages for drug absorption and many approaches have been developed. CDDS rely on the colon's distinct pH, transit time, microflora and enzymes to trigger drug release. They include pH-sensitive coatings, prodrugs, polysaccharide matrices and time-delayed systems. In vitro and in vivo tests evaluate release profiles under gastrointestinal conditions while imaging techniques track systems in the colon. CDDS provide localized treatment with fewer side effects compared to traditional therapies.
This document discusses pharmaceutical approaches to colon targeted drug delivery systems. It begins with an introduction to colon targeted drug delivery and the advantages of this approach. It then describes the anatomy and physiology of the colon, factors governing colonic drug delivery, and various strategies that can be used for targeting drugs to the colon. These strategies include pH dependent delivery, time dependent delivery, pressure dependent delivery, and bacteria dependent delivery. The document also discusses different approaches for colon targeting, including coating with pH sensitive polymers and formulation of timed release systems. It reviews evaluation methods and some marketed products for colon targeted delivery systems, and concludes with discussing future prospects for this drug delivery approach.
RECENT ADVANCES IN COLON TARGETED DRUG DELIVERYVarun Girme
This document summarizes recent advances in colon targeted drug delivery. It discusses the anatomy and physiology of the colon, pharmaceutical approaches for targeting drugs to the colon like prodrug conjugates and coating technologies, evaluation methods for colon delivery systems including in vitro dissolution tests and gamma scintigraphy imaging. It also presents a case study on the formulation of 5-fluorouracil loaded chitosan nanoparticles with Eudragit S100 coating for colon cancer treatment, showing enhanced localized drug release at colonic pH.
FORMULATION AND INVITRO EVALUATION OF COLON SPECIFIC DRUG DELIVERY SYSTEM BY ...alok prakash kar
The document describes the formulation and in vitro evaluation of a colon-specific drug delivery system containing metronidazole. Metronidazole tablets were prepared using different polymers like ethyl cellulose, cellulose acetate butyrate, and Eudragit polymers. The tablets were then coated with various polymer coating suspensions. The coated tablets were evaluated for film thickness, weight gain, hardness, disintegration time, and drug release. The results showed that the coating thickness and weight gain increased with increasing polymer concentration in the coating suspension. The coated tablets had suitable hardness and disintegration times while sustaining drug release in the acidic environment of the stomach.
This presentation related to targeted drug delivery system particularly to colonic region. It includes various approaches for colonic delivery of drug.
Colon specific drug delivery system approaches and applicationTukaram Patil
This document discusses colon specific drug delivery approaches and applications. It begins with an introduction explaining the advantages of targeting drug delivery to the colon and protecting drugs from the upper gastrointestinal tract. It then discusses various factors that affect colonic drug absorption and several primary and new approaches for colon targeted drug delivery systems, including pH sensitive polymers, delayed release systems, and microbial triggered delivery. Examples of different delivery approaches like pulsincap systems, pressure controlled systems, and prodrug approaches are also described. The document concludes that colon targeted delivery offers benefits over traditional systems and novel approaches provide more specific delivery than primary methods.
This document summarizes a seminar presentation on colon-specific drug delivery. It discusses targeting delivery of drugs to the colon to treat diseases like ulcerative colitis and Crohn's disease. Various pharmaceutical approaches for colon-specific delivery are described, including pH sensitive systems, microbial triggered systems, and time release systems. Platform technologies for colon delivery like PULSINCAP and OROS-CT are also outlined. The document concludes that colonic drug delivery presents many challenges but also opportunities to improve therapy for colonic diseases.
This document provides an overview of colon specific drug delivery systems. It discusses the advantages of targeting drug delivery to the colon which includes reduced dosing, lower side effects, and improved patient compliance. It also reviews some limitations such as multiple manufacturing steps and potential for drug degradation by colonic microflora. The document then examines the anatomy and physiology of the colon, factors that influence colonic drug delivery such as pH and transit time, and how drugs are absorbed in the colon. It concludes by outlining several approaches to colon specific drug delivery including pH dependent coatings, time release systems, prodrugs activated by colonic bacteria, and the use of carriers degraded by colonic microflora.
colon drug delivery- advantage and disadvantage of colon delivery, anatomy of colon in healthy and diseased state , different approaches (conventional and new) for colon delivery, in vitro and in vivo evaluation
Colon-specific drug delivery (CDDS) aims to target drug release and absorption in the colon for local treatment of colonic diseases or systemic delivery of proteins and peptides. The document discusses the anatomy and physiology of the colon, factors governing colonic drug delivery, and various pharmaceutical approaches for CDDS including pH-sensitive systems, microbially triggered systems, and timed or controlled release platforms. Evaluation methods for CDDS include in vitro drug release tests under simulated gastric and intestinal conditions and in vitro enzymatic degradation assays.
The document discusses colon targeted drug delivery systems. It begins by defining colon targeted drug delivery as targeting drugs to the lower parts of the GI tract, mainly the large intestine. This is done for various objectives like reducing dosing frequency or delivering drugs that would otherwise be degraded. Approaches to colon targeting include pH sensitive coatings, microbially triggered systems, and timed release. Evaluation methods include in vitro dissolution tests and studies using animal models. Key advantages are site specific delivery and protecting drugs from degradation, while challenges include multiple manufacturing steps and drug binding in the colon.
This document discusses various pharmaceutical approaches for colon specific drug delivery systems. It begins with an introduction to colon specific drug delivery and the physiological considerations. It then describes various approaches in detail, including covalent linkage of drugs to carriers like azo conjugates, cyclodextrin conjugates, and polymeric prodrugs. It also discusses approaches to deliver intact molecules to the colon using coatings with pH sensitive or biodegradable polymers, embedding in matrices, timed release systems, and more. The document provides examples and details for each approach. It concludes with a brief section on evaluating colon specific drug delivery systems.
This document discusses colon targeted drug delivery systems. The major goals of targeted drug delivery are to selectively deliver drugs to the colon at therapeutic concentrations while limiting access to non-target sites. Approaches to colon targeted delivery include pH sensitive polymers, time dependent systems, and formulations triggered by colonic microflora. Several marketed drugs use these approaches including mesalamine, budesonide, and olsalazine. Challenges to colon delivery include biological barriers in the GI tract, variation in gastric emptying and colonic pH, and impact of colonic microflora on drug activity.
The document discusses drug delivery to the colon and various approaches for targeted colon drug delivery systems. It provides information on the anatomy and physiology of the colon, factors influencing drug absorption in the colon, and diseases associated with the colon. Various primary and new approaches for colon targeted drug delivery are described, including pH sensitive polymers, time controlled systems, and microbiologically triggered systems. Evaluation methods for these systems include in vitro and in vivo testing.
This document discusses colon-specific drug delivery systems. It begins with an introduction to colon targeting and why it is important for treating colonic disorders. It then covers factors to consider in design such as colon anatomy, pH, transit time and microflora. Approaches discussed include pH dependent, time dependent and bacteria dependent systems. It evaluates both in vitro and in vivo methods for testing colon delivery systems.
Introduction, Anatomy of colon, Advantage of colon drug delivery system, Disadvantage of colon drug delivery system, Factors influencing CDDS, Approaches of CDDS, Evaluation of CDDS
Pulsatile drug delivery systems presentationchiranjibi68
This seminar discusses pulsatile drug delivery systems, which deliver drugs according to circadian rhythms to time their release when diseases are most active. Such systems provide a lag time followed by a rapid and complete drug release. This allows drugs to be delivered at the right time, amount, and site of action. Pulsatile delivery provides benefits like increased absorption, site targeting of drugs, reduced dosing, and less side effects. Various methods were presented including single and multiple unit systems using coatings that erode, rupture or allow osmotic pumping at the desired time. Marketed technologies like OROS and Pulsincap were highlighted. Pulsatile delivery holds promise for improving treatment of chronic diseases like asthma, arthritis and
DESIGN AND ASSESSMENT OF COLON SPECIFIC DRUG DELIVERY OF CELECOXIB USING PU...Lakshmi
The document summarizes the design and assessment of a colon-specific drug delivery system for celecoxib using pulsincap technique. Celecoxib microcrystals were prepared using a rapid solvent change method and evaluated. The microcrystals were then used to prepare pulsincaps containing hydrogel plugs to provide a lag time before drug release. In vitro drug release studies were conducted on the pulsincaps to assess their ability to deliver celecoxib in a pulsatile manner to the colon. The aim was to improve solubility, target delivery to the colon, and minimize dosing frequency for the treatment of rheumatoid arthritis.
This document presents information on colon targeted drug delivery systems. It discusses the colon as a site for drug absorption and lists some advantages of colon targeted delivery such as reduced dosing frequency and protection of drugs from degradation in the stomach and small intestine. It describes various approaches for colon targeting including prodrug, pH dependent, time dependent, and bacterial activated systems. It provides examples of marketed colon targeted formulations and discusses factors that can influence drug absorption in the colon such as gastrointestinal diseases and transit time.
This document summarizes colon targeted drug delivery systems. It discusses pH dependent systems, time dependent systems, and microbially triggered systems as primary approaches. It also discusses newer approaches like pressure controlled colon delivery capsules and complex delivery systems (CODES). Advantages of colon targeted delivery include protection of drugs from degradation in the stomach and small intestine and targeting delivery to the colon for local treatment of diseases like IBD or systemic delivery of proteins and peptides. Novel drug delivery systems discussed include nano systems for targeted delivery to the colon to treat diseases like IBD and colon cancer.
Colon-specific drug delivery systems (CDDS) are desirable for the treatment of a range of local diseases such as ulcerative colitis, amebiasis ,irritable bowel syndrome, Crohn’s disease, chronic pancreatitis and colon cancer.
This document discusses targeted drug delivery to the colon. It begins with an introduction to colon targeted drug delivery and describes the anatomy and physiology of the colon. Key criteria for drug selection include drugs used to treat gastrointestinal diseases, those poorly absorbed in the upper GI tract, and drugs that degrade in the stomach and small intestine. Approaches for colon targeting include pH sensitive systems, microbially triggered systems using prodrugs and polysaccharides, timed release systems, and osmotically controlled drug delivery systems. The colon offers advantages for drug delivery including treatment of colonic diseases and absorption of proteins and peptides.
This document reviews approaches for colon-specific drug delivery (CDDS). It compares earlier approaches like prodrugs, pH-dependent systems, and microbial-triggered systems, which had limitations, to newer approaches like pressure-controlled colonic delivery capsules, CODESTM, and osmotic controlled drug delivery (ORDS-CT) systems. These novel approaches are unique in achieving in vivo site specificity and feasibility of manufacturing. Factors that must be considered in colon targeted drug delivery system design include anatomy and physiology of the colon, pH levels in different colon regions, colonic microflora and enzymes, transit of materials through the colon, and drug absorption in the colon.
Gastro retentive drug delivery system (GRDDS)Shweta Nehate
This document discusses gastro-retentive drug delivery systems (GRDDS), which aim to prolong the gastric residence time of drugs and target drug release in the upper gastrointestinal tract. It describes the physiology of the gastrointestinal tract and potential drug candidates for GRDDS. Various approaches for GRDDS are covered, including floating, high density, bioadhesive, swelling, and superporous hydrogel systems. Evaluation parameters, applications, marketed formulations, and conclusions about GRDDS are also summarized.
2.colon specific drug delivery system 2 nd semHanmant Galande
This document summarizes a seminar presentation on colon-specific drug delivery systems. It discusses factors to consider in designing such systems like anatomy, pH, transit time and microflora of the colon. Approaches covered include pH dependent coatings, time dependent controlled release systems and bacterial degradation of polymers or prodrugs. Evaluation methods discussed are in vitro drug release studies under gastric and intestinal conditions and in vivo techniques like animal models, string tests, endoscopy, radiography and scintigraphy. The document provides an overview of colon targeting strategies and assessment of colon delivery systems.
The document discusses colon targeting for drug delivery. It begins with the anatomy and physiology of the colon, noting its segments. It then discusses the rationale for colon targeting, including local treatment of diseases and delivery of unstable drugs. Several approaches for colon targeting are described, including pH-sensitive coatings, microbially-triggered systems, and prodrugs. Natural polysaccharides, time release systems, and osmotically controlled systems are also summarized as approaches for colon targeting. In conclusion, colon targeting provides advantages for local therapy and improved drug delivery but remains challenging.
review on gastroretentive drug delivery systemsMaedeh Haedi
This document discusses gastroretentive drug delivery systems (GRDDS). GRDDS are used to prolong the gastric residence time and target drug release in the upper gastrointestinal tract. There are various types of GRDDS including floating systems, expandable systems, and mucoadhesive systems. The document discusses factors that affect GRDDS performance such as pharmaceutical factors like polymer selection and dosage form properties, as well as physiological factors. Specific polymers commonly used in GRDDS formulations are also described, such as sodium alginate, carbopol, and hydroxypropyl methylcellulose.
This document provides an overview of sustained and controlled drug delivery systems (SR and CRDDS). It defines SR and CRDDS and compares their drug release profiles. The advantages include improved bioavailability and compliance while disadvantages include dose dumping and adjustment difficulties. Drugs are selected based on their physicochemical, pharmacokinetic, and pharmacodynamic properties. SR and CRDDS are classified into continuous release, delayed transit-continuous release, and delayed release systems. They are evaluated for properties like drug release and stability. Applications include oral, ocular, transdermal, and colonic delivery. Marketed products of these systems in tablets, capsules, and transdermal forms are also mentioned.
This document discusses gastroretentive drug delivery systems (GRDDS), which aim to prolong the gastric residence time of drugs to target drug release in the upper gastrointestinal tract. GRDDS are needed because oral drugs often have short gastric retention times and unpredictable emptying, resulting in incomplete drug release. The document outlines several approaches to achieving gastric retention, including floating, bioadhesive/mucoadhesive, expandable/unfoldable, and magnetic systems. It provides examples of drug candidates that could benefit from GRDDS and evaluates the advantages of these systems.
This document discusses gastro-retentive drug delivery systems (GRDDS). GRDDS are designed to prolong gastric residence time to allow for local or systemic drug release in the upper gastrointestinal tract. This can improve drug bioavailability and targeting of drugs. The document outlines the physiology of the stomach and various approaches to gastric retention, including floating, swelling, mucoadhesive, and magnetic systems. It provides examples of drug candidates suitable for GRDDS and advantages such as improved patient compliance and absorption of drugs that solubilize in the stomach. Evaluation methods and marketed GRDDS products are also summarized.
Noscapine based oral colon SpecificNanoparticles by Kuldipsinh Thakorkulu2929
This document discusses the design, development and evaluation of oral colon-specific nanoparticles of noscapiene for treating cancer. It begins with an introduction to the drug noscapiene and outlines the need, objectives and plan for the research. It then reviews relevant literature and patents. The materials and methodology, results and discussion are presented. It concludes with a summary and references. The overall aim is to develop a targeted colon-specific drug delivery system using noscapiene-loaded nanoparticles to treat colon cancer and related diseases while avoiding premature drug release in the stomach and small intestine.
This document discusses colonic specific drug delivery. It begins by introducing the rationale for colon targeted drug delivery of peptides and proteins, which are degraded in the stomach and small intestine. It then covers the anatomy and physiology of the colon, factors affecting colonic drug delivery, and various approaches for colon targeted systems. Key approaches discussed are pH dependent systems, which rely on polymers that dissolve at the higher pH of the colon, and microbially triggered systems, which are activated by enzymes in the colon.
Protein and peptide drug delivery seminar-97-2003-final2Pravin Chinchole
The document discusses protein and peptide drug delivery. It covers the introduction to proteins and peptides, routes of absorption, properties that present challenges for delivery, and various pharmaceutical approaches to overcome these challenges. These approaches include chemical modification through prodrug approaches, use of enzyme inhibitors, penetration enhancers, and formulation vehicles like dry emulsions, microspheres, liposomes and nanoparticles. It also discusses stability aspects and recent advances in delivery of therapeutic proteins and peptides.
This document provides an overview of rectal drug delivery systems. It discusses the anatomy and physiology of the rectum, factors that influence drug absorption through the rectal route, and various rectal dosage forms including suppositories, enemas, and rectal capsules. The advantages of rectal delivery include avoidance of first-pass metabolism and use for patients who cannot swallow oral medications. Selection of drugs for the rectal route depends on their physicochemical properties and therapeutic dose. Evaluation methods for rectal formulations include in vitro tests and animal studies.
sustained and controlled Drug delivery systemSripriyasekar1
This document provides an overview of sustained and controlled drug delivery systems (SR and CRDDS). It defines SR and CRDDS and compares their drug release profiles. Advantages include improved bioavailability and compliance due to reduced dosing frequency. Disadvantages include dose dumping and stability issues. Drugs are selected based on properties like solubility, half-life and metabolism. Systems are classified as continuous release, delayed transit/release, or colonic release. Evaluation involves testing release profiles, stability, and bioavailability. Applications include oral, ocular, transdermal and site-specific delivery. Marketed products are mentioned and the document concludes SR and CRDDS can increase efficacy and safety.
Recent Advances in Colon Targeted Drug Delivery SystemDarshil Shah
Colon Targeted Drug delivery is the most convenient and desirable drug targeting method for the drugs which degrades in acidic environment, and also preferable for prolong or delayed release and also desease specisic to colon.
The all the content in this profile is completed by the teachers, students as well as other health care peoples.
thank you, all the respected peoples, for giving the information to complete this presentation.
this information is free to use by anyone.
Similar to A REVIEW ON COLON TARGATED DRUG DELIVERY SYSTEM (20)
Phenomics assisted breeding in crop improvementIshaGoswami9
As the population is increasing and will reach about 9 billion upto 2050. Also due to climate change, it is difficult to meet the food requirement of such a large population. Facing the challenges presented by resource shortages, climate
change, and increasing global population, crop yield and quality need to be improved in a sustainable way over the coming decades. Genetic improvement by breeding is the best way to increase crop productivity. With the rapid progression of functional
genomics, an increasing number of crop genomes have been sequenced and dozens of genes influencing key agronomic traits have been identified. However, current genome sequence information has not been adequately exploited for understanding
the complex characteristics of multiple gene, owing to a lack of crop phenotypic data. Efficient, automatic, and accurate technologies and platforms that can capture phenotypic data that can
be linked to genomics information for crop improvement at all growth stages have become as important as genotyping. Thus,
high-throughput phenotyping has become the major bottleneck restricting crop breeding. Plant phenomics has been defined as the high-throughput, accurate acquisition and analysis of multi-dimensional phenotypes
during crop growing stages at the organism level, including the cell, tissue, organ, individual plant, plot, and field levels. With the rapid development of novel sensors, imaging technology,
and analysis methods, numerous infrastructure platforms have been developed for phenotyping.
The use of Nauplii and metanauplii artemia in aquaculture (brine shrimp).pptxMAGOTI ERNEST
Although Artemia has been known to man for centuries, its use as a food for the culture of larval organisms apparently began only in the 1930s, when several investigators found that it made an excellent food for newly hatched fish larvae (Litvinenko et al., 2023). As aquaculture developed in the 1960s and ‘70s, the use of Artemia also became more widespread, due both to its convenience and to its nutritional value for larval organisms (Arenas-Pardo et al., 2024). The fact that Artemia dormant cysts can be stored for long periods in cans, and then used as an off-the-shelf food requiring only 24 h of incubation makes them the most convenient, least labor-intensive, live food available for aquaculture (Sorgeloos & Roubach, 2021). The nutritional value of Artemia, especially for marine organisms, is not constant, but varies both geographically and temporally. During the last decade, however, both the causes of Artemia nutritional variability and methods to improve poorquality Artemia have been identified (Loufi et al., 2024).
Brine shrimp (Artemia spp.) are used in marine aquaculture worldwide. Annually, more than 2,000 metric tons of dry cysts are used for cultivation of fish, crustacean, and shellfish larva. Brine shrimp are important to aquaculture because newly hatched brine shrimp nauplii (larvae) provide a food source for many fish fry (Mozanzadeh et al., 2021). Culture and harvesting of brine shrimp eggs represents another aspect of the aquaculture industry. Nauplii and metanauplii of Artemia, commonly known as brine shrimp, play a crucial role in aquaculture due to their nutritional value and suitability as live feed for many aquatic species, particularly in larval stages (Sorgeloos & Roubach, 2021).
The binding of cosmological structures by massless topological defectsSérgio Sacani
Assuming spherical symmetry and weak field, it is shown that if one solves the Poisson equation or the Einstein field
equations sourced by a topological defect, i.e. a singularity of a very specific form, the result is a localized gravitational
field capable of driving flat rotation (i.e. Keplerian circular orbits at a constant speed for all radii) of test masses on a thin
spherical shell without any underlying mass. Moreover, a large-scale structure which exploits this solution by assembling
concentrically a number of such topological defects can establish a flat stellar or galactic rotation curve, and can also deflect
light in the same manner as an equipotential (isothermal) sphere. Thus, the need for dark matter or modified gravity theory is
mitigated, at least in part.
EWOCS-I: The catalog of X-ray sources in Westerlund 1 from the Extended Weste...Sérgio Sacani
Context. With a mass exceeding several 104 M⊙ and a rich and dense population of massive stars, supermassive young star clusters
represent the most massive star-forming environment that is dominated by the feedback from massive stars and gravitational interactions
among stars.
Aims. In this paper we present the Extended Westerlund 1 and 2 Open Clusters Survey (EWOCS) project, which aims to investigate
the influence of the starburst environment on the formation of stars and planets, and on the evolution of both low and high mass stars.
The primary targets of this project are Westerlund 1 and 2, the closest supermassive star clusters to the Sun.
Methods. The project is based primarily on recent observations conducted with the Chandra and JWST observatories. Specifically,
the Chandra survey of Westerlund 1 consists of 36 new ACIS-I observations, nearly co-pointed, for a total exposure time of 1 Msec.
Additionally, we included 8 archival Chandra/ACIS-S observations. This paper presents the resulting catalog of X-ray sources within
and around Westerlund 1. Sources were detected by combining various existing methods, and photon extraction and source validation
were carried out using the ACIS-Extract software.
Results. The EWOCS X-ray catalog comprises 5963 validated sources out of the 9420 initially provided to ACIS-Extract, reaching a
photon flux threshold of approximately 2 × 10−8 photons cm−2
s
−1
. The X-ray sources exhibit a highly concentrated spatial distribution,
with 1075 sources located within the central 1 arcmin. We have successfully detected X-ray emissions from 126 out of the 166 known
massive stars of the cluster, and we have collected over 71 000 photons from the magnetar CXO J164710.20-455217.
Immersive Learning That Works: Research Grounding and Paths ForwardLeonel Morgado
We will metaverse into the essence of immersive learning, into its three dimensions and conceptual models. This approach encompasses elements from teaching methodologies to social involvement, through organizational concerns and technologies. Challenging the perception of learning as knowledge transfer, we introduce a 'Uses, Practices & Strategies' model operationalized by the 'Immersive Learning Brain' and ‘Immersion Cube’ frameworks. This approach offers a comprehensive guide through the intricacies of immersive educational experiences and spotlighting research frontiers, along the immersion dimensions of system, narrative, and agency. Our discourse extends to stakeholders beyond the academic sphere, addressing the interests of technologists, instructional designers, and policymakers. We span various contexts, from formal education to organizational transformation to the new horizon of an AI-pervasive society. This keynote aims to unite the iLRN community in a collaborative journey towards a future where immersive learning research and practice coalesce, paving the way for innovative educational research and practice landscapes.
Or: Beyond linear.
Abstract: Equivariant neural networks are neural networks that incorporate symmetries. The nonlinear activation functions in these networks result in interesting nonlinear equivariant maps between simple representations, and motivate the key player of this talk: piecewise linear representation theory.
Disclaimer: No one is perfect, so please mind that there might be mistakes and typos.
dtubbenhauer@gmail.com
Corrected slides: dtubbenhauer.com/talks.html
ESR spectroscopy in liquid food and beverages.pptxPRIYANKA PATEL
With increasing population, people need to rely on packaged food stuffs. Packaging of food materials requires the preservation of food. There are various methods for the treatment of food to preserve them and irradiation treatment of food is one of them. It is the most common and the most harmless method for the food preservation as it does not alter the necessary micronutrients of food materials. Although irradiated food doesn’t cause any harm to the human health but still the quality assessment of food is required to provide consumers with necessary information about the food. ESR spectroscopy is the most sophisticated way to investigate the quality of the food and the free radicals induced during the processing of the food. ESR spin trapping technique is useful for the detection of highly unstable radicals in the food. The antioxidant capability of liquid food and beverages in mainly performed by spin trapping technique.
2. Introduction
Anatomy of colon
Criteria of drug selection
Approaches of colon targeting
EVALUATION
INNOVATIVE DEVICES
Conclusion
Reference
22-May-17 RESN 2
3. Targeted drug delivery into the colon is highly
desirable for local treatment of a variety of bowel
diseases such as ulcerative colitis, Crohn’s disease,
amoebiasis, colonic cancer, local treatment of
colonic pathologies, and systemic delivery of
protein and peptide drugs, NSAIDs, steroids.
The colon is believed to be a suitable absorption site
for peptides and protein drugs for the following
reasons; (i) less diversity, and intensity of digestive
enzymes, (ii) less proteolytic activity of colon
mucosa than that of small intestine.
22-May-17 RESN 3
4. Colon targeting diseases, drugs and sites
Targetsites Disease conditions Drugand activeagents
Topical action Inflammatory Bowel
Diseases, Irritable bowel
disease and Crohn’s disease.
Chronic pancreatitis
Hydrocortisone,
Budenoside,
Prednisolone, Sulfaselazine,
Olsalazine, Mesalazine,
Balsalazide
Local action Pancreatactomy and cystic
fibrosis, Colorectal cancer
Digestive enzyme
supplements
5-Flourouracil
Systemic action To prevent gastric irritation
To prevent first pass
metabolism of orally ingested
drugs
Oral delivery of peptides
Oral delivery of vaccines
NSAIDS
Steroids
Insulin
22-May-17 RESN
4
5. ANATOMY OF COLON
The GI tract is divided into the stomach and
the small and large intestine. The large
intestine extending from the ileocecal
junction to the anus, is divided into three
main parts. These are the colon, the rectum
and the anal canal.
For the purpose of colonic drug delivery,
there are two important physiological
factors to be considered these are pH and
GI transit time.
The mid and left colon have pH values of
approximately 6.6 and 7.0. Interspecies
variability in pH is a major concern when
developing and testing colon-specific
delivery systems
Figure 1. Anatomy of large intestine
22-May-17 RESN
5
6. Table 2. pH in the GI tract
Location pH
Oral cavity 6.2-7.4
Oesophagus 5.0-6.0
Stomach Fasted condition: 1.5-2.0
Fed condition: 3.0-5.0
Small intestine Jejunum: 5.0-6.5
Ileum: 6.0-7.5
Large intestine Right colon: 6.4
Mid colon and left colon:
6.0-7.6
22-May-17 RESN 6
7. Drugs used for local effects in colon against GIT
diseases.
Drugs poorly absorbed from upper GIT.
Drugs for colon cancer.
Drugs that degrade in stomach and small intestine.
Drugs that undergo extensive first pass metabolism.
Drugs for targeting.
22-May-17 RESN 7
8. 22-May-17 RESN 8
Covalent linkage of drug with carriers
pH sensitive systems
Microbial triggered systems
Timed release systems
Osmotic controlled systems
Bioadhesive systems
Pressure dependent release systems
9. 22-May-17 RESN
9
PRIMARYAPPROACHES NEWAPPROACHES
pH Sensitive Polymer
Coated Drug Delivery to the
Colon
Delayed Release Drug
Delivery to Colon
Microbially Triggered
Drug Delivery to Colon
Pressure Controlled
Drug-Delivery Systems
Novel Colon Targeted
Delivery System
(CODESTM)
Osmotic Controlled
Drug Delivery (ORDS-
CT)
10. The pH in the transverse colon is 6.6 and 7.0 in the
descending colon. Use of pH dependent polymers is
based on these differences in pH levels.
The polymers described as pH dependent in colon
specific drug delivery are insoluble at low pH levels
but become increasingly soluble as pH rises.
These processes distribute the drug throughout the
large intestine and improve the potential of colon
targeted delivery systems.
22-May-17 RESN 10
12. Time controlled release system (TCRS) such as sustained or
delayed release dosage forms are also very promising drug
release systems.
The dosage forms may also be applicable as colon targeting
dosage forms by prolonging the lag time of about 5 to 6 h.
Enteric coated time-release press coated (ETP) tablets, are
composed of three components, a drug containing core tablet, the
press coated swellable hydrophobic polymer layer, and an enteric
coating layer.
22-May-17 RESN
12Figure 2. Design of ETP
13. The microflora of the colon is in the range of 1011 -1012 CFU/ mL,
consisting mainly of anaerobic bacteria, e.g. bacteroides,
bifidobacteria, eubacteria, clostridia, enterococci, enterobacteria and
ruminococcus etc.
Microflora produces a vast number of enzymes like glucoronidase,
xylosidase, arabinosidase, galactosidase, nitroreductase,
azareducatase, deaminase, and urea dehydroxylase.
Presence of the biodegradable enzymes only in the colon, the use of
biodegradable polymers for colon-specific drug delivery.
These polymers shield the drug from the environments of stomach
and small intestine, and are able to deliver the drug to the colon.
22-May-17 RESN
13
14. A Prodrug is a pharmacologically inactive derivative of a
parent molecule that require some form of transformation in
vivo to release the active drug at the target site.
This approach involves covalent linkage between the drug and
its carrier.
Biotransformation is carried out by a variety of enzymes,
mainly of bacterial origin, present in the colon. The enzymes
that are mainly targeted for colon drug delivery include
azoreducatase-galactosidase, β- xylosidase, nitroreductase,
glycosidase deaminase, etc.
22-May-17 RESN 14
15. The azo linkage exhibits a
wide range of thermal,
chemical, photochemical and
pharmaceutical properties.
The azo compounds are
extensively metabolized by
the intestinal bacteria.
Sulphasalazine, which was
used for the treatment of
rheumatoid arthritis. This
compound has an azo bond
between 5-ASA and
sulphapyridine.
Include naturally occurring
polysaccharides obtained
from plant (guar gum, inulin),
animal (chitosan, chondrotin
sulphate), algal (alginates) or
microbial (dextran) origin.
The polysaccrides can be
broken down by the colonic
microflora to simple
saccharides. Therefore, they
fall into the category of
“generally regarded as safe”
(GRAS).
22-May-17 RESN
15
AZOREDUCTASES POLYSACCHARIDASES
17. Like prodrug, a number of naturally occuring polysaccharides are stable
in the upper intestine but susceptible to hydrolytic degradation in the
colon.
Most polysaccharides can be chemically modified to optimize specific
properties, such as the ability to form impermeable films. Some of them
are:-
22-May-17 RESN
17
POLYSACCHARIDE APPLICATIONS
Pectin & its salt form Matrices, enteric coated matrix
tablet
Chitosan & its derivative Coated capsule, microsphere
Cross linked dextran Hydrogels
Table 4. Polysaccharide based materials used to deliver drug to colon.
18. Due to peristalsis, higher pressures are encountered in the colon
than in the small intestine.
Takaya et al. developed pressure controlled colon-delivery
capsules prepared using ethylcellulose, which is insoluble in
water.
In such systems, drug release occurs following the disintegration
of a water insoluble polymer capsule because of pressure in the
lumen of the colon.
The thickness of the ethylcellulose membrane is the most
important factor for the disintegration of the formulation.
22-May-17 RESN 18
19. CODESTM is a combined approach of pH dependent and
microbially triggered CDDS.
CODESTM is an unique CDDS technology that was designed to
avoid the inherent problems associated with pH or time dependent
systems
It has been developed by utilizing a unique mechanism involving
lactulose, which acts as a trigger for site specific drug release in
the colon.
22-May-17 RESN 19
20. Lactulose
Organic acid
Microflora
In colon
In small
intestine
In stomach Enteric coating
Acid soluble
polymer (only
slightly permeable)
Figure 4. Schematic design of CODESTM
22-May-17 RESN
20
21. The OROS-CT (Alza corporation) can be used to target the
drug locally to the colon for the treatment of disease or to
achieve systemic absorption.
The OROS-CT system can be a single osmotic unit or may
incorporate as many as 5-6 push-pull units, each 4 mm in
diameter, encapsulated within a hard gelatin capsule.
For treating ulcerative colitis, each push pull unit is designed
with a 3-4 h post gastric delay to prevent drug delivery in the
small intestine. Drug release begins when the unit reaches the
colon.
OROS-CT units can maintain a constant release rate for up to
24 hours in the colon or can deliver drug over a period as
short as four hours.
22-May-17 RESN
21
23. For evaluation, not any standardized evaluation
technique is available for evaluation of CDDS
because an ideal in vitro model should posses the in-
vivo conditions of GIT such as pH, volume, stirring,
bacteria, enzymes, enzyme activity, and other
components of food.
These conditions are influenced by the diet, physical
stress, and these factors make it difficult to design a
standard in-vitro model.
22-May-17 RESN
23
24. In-vitro dissolution test.
In-vitro enzymatic test.
In-vivo evaluation.
Drug Delivery Index (DDI) and Clinical Evaluation of Colon-
Specific Drug Delivery Systems
22-May-17 RESN 24
25. The development of an oral, universally applicable, colonic drug
delivery system represents a considerable challenge to the
pharmaceutical scientist.
Consideration must not only be given to ways in which drug
release in the colon can be achieved, but also to the behaviour and
environmental conditions experienced by the dosage form prior to
reaching the colon.
A major problem in comparing different delivery systems is the
fact that degradation studies are performed under different
conditions.
22-May-17 RESN 25
26. Philip AK, Philip B. Colon Targeted Drug Delivery Systems: A
Review on Primary and Novel Approaches. Oman Medical Journal
2010; 25(2): 1-3,6-7.
Kinget R, Kalala W, Vervoort L and Mooter GVD. Journal of Drug
Targeting 1998; 6(2): 130-131.
Vinaykumar KV, Sivakumar T, Tamizhmani T, Sundar TR, Sarath
IC. Colon targeting drug delivery system: A review on recent
approaches. Int J Pharm Biomed Sci 2011; 2(1): 14.
Ashford M and Fell JT. Targeting Drugs to the Colon: Delivery
Systems for Oral Administration. Journal of Drug Targeting, 1994;
2: 241,254.
22-May-17 RESN 26
27. T H A N K Y O U
22-May-17 27
Presentation :
k.umamaheswara rao
Editor's Notes
COLON TARGATING DRUG DELIVERY SYSTEM PREPARED BY K.UMAMAHESWARA RAO , UNDER THE GUIDENCE OF MR.ANUDEEP
CONTENTS TO A REVIEW ON COLON TARGATING DRUG DELIVERY SYSTEM
Targeted drug delivery into the colon is highly desirable for local treatment of a variety of bowel diseases such as ulcerative colitis, Crohn’s disease, amoebiasis, colonic cancer, local treatment of colonic pathologies, and systemic delivery of protein and peptide drugs, NSAIDs, steroids.
The colon is believed to be a suitable absorption site for peptides and protein drugs for the following reasons; (i) less diversity, and intensity of digestive enzymes, (ii) less proteolytic activity of colon mucosa than that of small intestine ( A UMAMAHESWARARO REVIEW )
ANATOMY OF COLON
CONDITIONS OF G.I.T
Criteria of drug selection
APPROCHES TO FORM A ACCURATE DRUG DELIVERY
pH Sensitive Polymer Coated Drug Delivery to the Colon
COLON TARGETED DRUG DELIVERY SYSTEM A REVIEW
COLON TARGETED DRUG DELIVERY SYSTEM A REVIEW
COLON TARGETED DRUG DELIVERY SYSTEM A REVIEW
PRODRUG
COLON TARGETED DRUG DELIVERY SYSTEM A REVIEW
COLON TARGETED DRUG DELIVERY SYSTEM A REVIEW
COLON TARGETED DRUG DELIVERY SYSTEM A REVIEW
COLON TARGETED DRUG DELIVERY SYSTEM A REVIEW
COLON TARGETED DRUG DELIVERY SYSTEM A REVIEW
COLON TARGETED DRUG DELIVERY SYSTEM A REVIEW
COLON TARGETED DRUG DELIVERY SYSTEM A REVIEW
COLON TARGETED DRUG DELIVERY SYSTEM A REVIEW
COLON TARGETED DRUG DELIVERY SYSTEM A REVIEW
COLON TARGETED DRUG DELIVERY SYSTEM A REVIEW
COLON TARGETED DRUG DELIVERY SYSTEM A REVIEW
CONCLUSION
COLON TARGETED DRUG DELIVERY SYSTEM A REVIEW
REFERENCE